Hepion Pharmaceuticals HEPA

Hepion Pharmaceuticals, Inc. is a medical diagnostic company headquartered in Red Bank, New Jersey. The company focuses on the development of diagnostic tools for chronic liver diseases. Previously, it was engaged in the development of drug therapies for liver disease treatment. Its activities are now centered on diagnostic assets acquired through licensing agreements. Hepion Pharmaceuticals operates in the healthcare sector, specifically within the medical diagnostics industry. The company has not yet commercialized any products and remains in the development stage.

Hepion Pharmaceuticals, Inc. does not currently generate revenue from operations. The company has not commercialized any of its medical diagnostic products. Revenue generation is not expected for several years, if at all. All activities are currently funded through external financing rather than product sales. The company has reported zero revenue from inception through March 31, 2026. Financial resources are directed toward research, development, and administrative functions.

The company operates through the following segments: diagnostic assets.

• Diagnostic assets: This segment includes liver disease diagnostic tools acquired from Cirna Diagnostics, LLC. The assets consist of three products that have received CE marking. These products are eligible for sale in the European Union and other markets accepting the CE mark. The segment does not currently include any products approved for sale in the United States. Hepion Pharmaceuticals, Inc. paid an upfront fee and assumes responsibility for certain patent expenses related to these assets.

Hepion Pharmaceuticals, Inc. operates as a preclinical and development-stage company in the medical diagnostics field. It does not yet hold a commercial market position due to the absence of approved products. The company competes with other entities developing liver disease diagnostics and therapeutics. Its competitive position is limited by the lack of commercialized offerings and reliance on future regulatory approvals. Hepion Pharmaceuticals differentiates itself through its focus on chronic liver disease diagnostics, though it has not yet established market traction.

Hepion Pharmaceuticals, Inc. serves no current customers as it has not commercialized any products. The company does not list specific customer names in its filings. Its intended customer base includes healthcare providers, hospitals, and clinics specializing in liver disease management. Future customers may include distributors and medical institutions in regions accepting CE-marked diagnostic products. Until regulatory approvals are obtained, the company maintains no active customer relationships.